Research suggests that cdk4/6 inhibition may reduce the expansion of tp53-mutant clonal hematopoiesis that can occur as a result of chemotherapy. This finding implies a potential therapeutic strategy for mitigating a specific type of hematopoietic change associated with chemotherapy. The role of cdk4/6 inhibition in this context appears to be one of mitigation, rather than elimination, of the expansion of mutant cells.